Trends in epidemiology and treatment and outcome for head and neck cancer: A population-based long-term analysis from 1996 to 2011 of the Thuringian cancer registry

Guntinas‐Lichius, Orlando; Wendt, Thomas; Kornetzky, Nicole; Buentzel, Jens; Eßer, Dirk; Böger, D; Müller, Andréas; Schultze‐Mosgau, Stefan; Schmalenberg, Harald

doi:10.1016/j.oraloncology.2014.09.015

Cited by 30 publications

(23 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A better outcome for patients with OSCC has repeatedly been reported in unselected case series, mainly due to an increase in the proportion of the HPV-positive patients [13]. In Germany, an increase in OSCC patients and survival improvement has been demonstrated in a population-based analysis [14]; however, up to 2010, HPV-associated OSCC still represented a minority (20%) of the OSCC cases in Germany, as shown here. In view of our low HPV rates and the consecutive selection of the patients, the 5-year OS rate of 48.8% lies within the range of the published large series.…”

Section: Discussionsupporting

confidence: 71%

Risk Factors for Overall Survival Outcome in Surgically Treated Human Papillomavirus-Negative and Positive Patients with Oropharyngeal Cancer

et al. 2017

View full text Add to dashboard Cite

Introduction: This study reports the oncological outcome of a non-selected series of patients with human papillomavirus(HPV)-positive and -negative oropharyngeal squamous cell carcinoma (OSCC) preferentially managed with upfront surgery. Methods: Consecutive OSCC cases (n = 378) diagnosed from 2000 to 2010 in our department were evaluated for risk factors, HPV association, therapy and overall survival (OS). HPV status was determined by combined DNA and p16 testing, and treatment was defined as the first course of treatment with any kind of surgery (upfront surgery) or primary chemoradiotherapy. OS of HPV-associated and HPV-negative patients was compared using Kaplan-Meier and multivariable Cox regression analyses. Results: The majority of OSCC patients (215 of 361; 69.5%) received upfront surgery as first-line treatment in curative intent. The 5-year OS rate in patients with HPV-positive and HPV-negative tumors were 81.1 and 39.7%, respectively. Upfront surgery in HPV-negative (p < 0.001) and HPV-positive patients (p = 0.05) resulted in improved OS only in advanced stages. Multivariate analysis for patients revealed age in HPV-associated OSCC as an independent predictor for improved survival, and age, performance, N status and therapy as independent predictors in HPV-negative OSCC. Conclusions: Non-selected OSCC patients amenable to curative therapy show poor 5-year OS. The benefit of upfront surgery remains unclear. A younger patient age was the main factor for a better outcome in patients with HPV-associated OSCC.

show abstract

Section: Discussionsupporting

confidence: 71%

Risk Factors for Overall Survival Outcome in Surgically Treated Human Papillomavirus-Negative and Positive Patients with Oropharyngeal Cancer

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Smoking and alcohol consumption are also regarded as major causal factors for other chronic diseases like cardiovascular or pulmonary diseases and may therefore contribute to the comorbidity of patients with head and neck cancer . Furthermore, about half of the patients with newly diagnosed head and neck cancer are older than 60 years of age . Older age itself is correlated with higher comorbidity .…”

Section: Introductionmentioning

confidence: 99%

Role of comorbidity on outcome of head and neck cancer: a population‐based study in Thuringia, Germany

et al. 2016

Self Cite

View full text Add to dashboard Cite

To examine the impact of comorbidity on overall survival (OS) in a population‐based study of patients with head and neck cancer who were treated between 2009 and 2011. Data of 1094 patients with primary head and neck carcinomas without distant metastasis from the Thuringian cancer registries were evaluated concerning the influence of patient's characteristics and comorbidity on OS. Data on comorbidity prior to head and neck cancer diagnosis was adapted to the Charlson Comorbidity (CCI), age‐adjusted CCI (ACCI), head and neck CCI (HNCCI), simplified comorbidity score (SCS), and to the Adult Comorbidity Evaluation–27 (ACE‐27). Most patients were male (80%; median age: 60 years; 50% stage IV tumors). Smoking, alcohol abuse, and anemia were registered for 38%, 33%, and 23% of the patients, respectively. Predominant therapy was surgery + radiochemotherapy (30%), surgery (29%), and surgery + radiotherapy (21%). Mean CCI, ACCI, HNCCI, SCS and ACE‐27 were 1.0 ± 1.5, 2.6 ± 2.1, 0.6 ± 0.8, 4.4 ± 4.2, and 0.9 ± 0.9, respectively. Median follow‐up was 25.7 months. Multivariable analyses showed that higher age, higher UICC stage, no therapy, including surgery or radiotherapy, alcohol abuse, and anemia, higher comorbidity were independent risk factors for worse OS (all P < 0.05). According to the discriminatory power analysis none of the five comorbidity scores was superior to the other scores to prognosticate OS. This population‐based study showed that comorbidity is frequent in German patients with head and neck cancer and is an important risk factor for poor OS. Comorbidity should be routinely assessed and taken into account in prospective clinical trials.

show abstract

“…The oral cavity subsite is the third most incident cancer of the upper aerodigestive tract . There has been only a slight increase in incidence of oral cavity cancer in Canada, which mimics the trend in other parts of the world . Roughly, 4300 Canadians (2900 men and 1400 women) were diagnosed with oral cavity (and oropharynx) cancer in 2014, and another 1150 Canadians would die of this disease…”

Section: Introductionmentioning

confidence: 99%

“…2 There has been only a slight increase in incidence of oral cavity cancer in Canada, which mimics the trend in other parts of the world. 3 Roughly, 4300 Canadians (2900 men and 1400 women) were diagnosed with oral cavity (and oropharynx) cancer in 2014, and another 1150 Canadians would die of this disease. 1 The primary treatment modality for oral cavity cancer is surgical resection with radiotherapy or chemoradiotherapy offered as adjuvant therapy to those with high-risk pathological features.…”

Section: Introductionmentioning

confidence: 99%

Overview of surgery for oral cavity cancer in Ontario

et al. 2016

View full text Add to dashboard Cite

show abstract

Trends in epidemiology and treatment and outcome for head and neck cancer: A population-based long-term analysis from 1996 to 2011 of the Thuringian cancer registry

Cited by 30 publications

References 33 publications

Risk Factors for Overall Survival Outcome in Surgically Treated Human Papillomavirus-Negative and Positive Patients with Oropharyngeal Cancer

Risk Factors for Overall Survival Outcome in Surgically Treated Human Papillomavirus-Negative and Positive Patients with Oropharyngeal Cancer

Role of comorbidity on outcome of head and neck cancer: a population‐based study in Thuringia, Germany

Overview of surgery for oral cavity cancer in Ontario

Contact Info

Product

Resources

About